By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
J&J's Q2 beat was driven by pharma, particularly Tremfya, but medtech underperformance and Abiomed's decline are concerns. The panel is neutral on the stock, with varying confidence levels.
Risk: Medtech underperformance and Abiomed's decline
Opportunity: Pharma momentum, especially Tremfya's growth
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
By Michael Erman
July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster Darzalex more than offset erosion from older products and a drop in sales for heart pumps it picked up in its 2022 acquisition of Abiomed.
J&J also increased its full-year sales and profit forecast.
The healthcare conglomerate reported second-quarter sales of $25.31 billion, up 6.6% from a year earlier and above analysts' average estimate of about $25.05 billion, according to LSEG data. Adjusted earnings were $2.90 per share, up 4.7% from a year ago and topping analyst expectations of $2.85.
It now expects sales of about $101.1 billion at the midpoint, from $100.8 billion previously. The company also raised its adjusted earnings per share forecast to $11.68 at the midpoint, from $11.55 previously.
The company said its pharmaceutical unit generated $16.38 billion in quarterly sales, ahead of analyst estimates of $16.1 billion.
Sales of its psoriasis and inflammatory bowel disease drug Tremfya rose 72.5% to $2 billion, compared with LSEG estimates of $1.74 billion. Tremfya has become increasingly important as J&J works to replace sales lost from Stelara, whose revenue has fallen sharply after losing its patent protection.
Second-quarter sales of blood cancer treatment Darzalex were $4.2 billion in the quarter, roughly in line with analyst estimates.
Sales at J&J's medical technology unit were $8.93 billion, slightly trailing analyst estimates.
CFO Joseph Wolk said in an interview that Abiomed sales in the quarter were hurt after publication of a U.K. study that raised questions about the use of Impella pumps during certain high-risk coronary procedures. Abiomed sales in the quarter fell 2% year over year, compared with 14% growth in the first quarter.
He said J&J expects the franchise to return to growth, particularly as the company releases more data showing the utility of the pumps.
"We have a big data set coming out probably in the first half of next year that should allay any fears," Wolk said. "When you have 28 platforms that generate at least $1 billion in revenue on an annual basis, we're not dependent on one asset."
(Reporting by Michael Erman; Editing by David Gregorio)
Four leading AI models discuss this article
"J&J's pharma strength drives a solid but not transformative beat, leaving the stock fairly valued at current multiples without clear re-rating catalyst."
J&J's Q2 beat (sales $25.31B vs $25.05B est., adj. EPS $2.90 vs $2.85) and raised FY guidance (sales midpoint to $101.1B, EPS to $11.68) reflect robust pharma momentum, especially Tremfya (+72.5% to $2B, beating $1.74B est.) offsetting Stelara erosion and Abiomed's 2% decline. With 28 $1B+ platforms, diversification cushions single-product risk. At ~15.5x forward P/E against mid-teens pharma growth, the stock looks fairly valued rather than cheap, but the upward revision signals confidence. Medtech softness and Impella study fallout remain near-term drags.
The raised guidance is modest (+0.3% on sales, +1.1% on EPS) and may already be priced in; Abiomed's UK-study hit and ongoing Stelara LOE pressure could accelerate if new data disappoints or biosimilar competition intensifies faster than modeled.
"J&J's reliance on Tremfya to offset the Stelara patent cliff creates a narrow path for growth that leaves little room for further operational stumbles in the MedTech division."
J&J’s beat is a classic 'quality over quantity' play, but the underlying mechanics are shifting. While the 72.5% jump in Tremfya is impressive, the reliance on high-growth blockbusters to mask the patent cliff of Stelara creates a high-stakes transition period. The MedTech miss is a red flag; the Abiomed contraction isn't just a U.K. study blip—it’s a reminder that M&A integration carries regulatory and clinical risks that can erode margins. Trading at roughly 14-15x forward earnings, J&J is fairly valued as a defensive anchor, but investors should watch for margin compression if the MedTech unit continues to lag while R&D spend on the pharma pipeline ramps up.
The market might be overreacting to the Abiomed headline, ignoring that J&J’s diversified 28-platform portfolio provides a level of cash-flow stability that makes the current valuation a bargain for long-term income investors.
"J&J's pharma beat masks a medtech slowdown and reliance on Stelara replacement revenue rather than genuine innovation, making FY25 guidance dependent on Abiomed's clinical narrative recovering in 2025."
J&J's beat is real but narrow—pharma upside (+$280M vs. estimates) masks medtech underperformance. Tremfya's 72.5% growth is impressive but built on Stelara patent cliff replacement, not new market expansion. Darzalex flat to estimates signals maturation. The Abiomed deceleration (14% Q1 growth to -2% Q2) is the red flag: a U.K. study tanked momentum on a $1B+ franchise, and management's reassurance about 'big data' in H1 2025 is promissory. Raising FY guidance by $130M sales and $0.13 EPS feels conservative given the beat, suggesting limited visibility beyond near-term tailwinds.
If Abiomed's growth doesn't recover post-data release, J&J's medtech unit—which trails estimates—becomes a drag on consolidated growth just as pharma blockbuster exclusivity windows narrow further. The company is guiding on hope, not certainty.
"The strongest risk to the positive read is that Tremfya and Darzalex growth prove unsustainable while Abiomed headwinds persist, potentially snapping the earnings beat in H2."
J&J beat on Tremfya and Darzalex and raised full-year guidance, but durability is uncertain. Tremfya’s 72.5% YoY surge looks driven by base effects as Stelara wanes, and competition from Skyrizi/Rinvoq plus payer pressure could cap further gains. Darzalex momentum may slow with newer myeloma therapies on the horizon. Abiomed weakness, tied to a UK study, shows how a single asset can drag a diversified portfolio, even as management touts data-readouts. The piece omits macro headwinds, FX exposure, and clearer pipeline visibility; the real test is whether core franchises can sustain mid-single-digit top-line growth amid patent cliffs and competitive pressure.
Tremfya’s huge quarterly gain is likely non-repeatable base effect, and Abiomed headwinds could persist; the Q2 beat may collapse if no new data READOUTs stabilize confidence.
"J&J's cash-flow stability and platform breadth make the current valuation more attractive than the narrow guidance implies."
Claude correctly flags the narrow beat and conservative guidance, but underplays how J&J's 28-platform diversification and $30B+ free cash flow provide a buffer against both Stelara LOE acceleration and Abiomed's UK-study volatility. The modest raise may reflect prudent visibility rather than weak conviction; at 15.5x forward P/E, any positive Impella data in H1 2025 could re-rate the multiple to 17x.
"J&J's pivot toward medtech acquisitions will structurally compress margins regardless of individual device data readouts."
Grok, your 17x re-rating thesis on Impella data ignores the structural reality: J&J’s medtech unit is increasingly a 'show-me' story, not a growth engine. Even if Impella stabilizes, the margin dilution from integrating high-cost acquisitions like Abiomed and Shockwave creates a persistent drag on consolidated operating margins. Investors aren't paying for potential; they are pricing in the inevitable margin compression as the company pivots from high-margin legacy pharma to lower-margin, capital-intensive medtech hardware.
"Medtech margin drag is cyclical, not structural; the re-rating hinges on Impella revenue stabilization timing, not just data release."
Gemini's margin-compression thesis assumes medtech integration drag persists indefinitely, but J&J's $30B+ FCF and 28-platform scale let them absorb near-term margin pressure without sacrificing shareholder returns. The real question: does Impella's installed base stabilize revenue *faster* than integration costs normalize? If yes, medtech becomes accretive by 2026. Grok's 17x re-rating isn't speculative—it's conditional on execution. Gemini conflates 'show-me' with 'doomed.'
"J&J’s ultimate rerating hinges on pharma durability (Stelara LOE trajectory), not on a perpetual medtech-margin drag."
Gemini, your margin-compression thesis hinges on Abiomed/M&A drag forever; history shows J&J's $30B+ FCF and 28-platform scale can absorb near-term headwinds and still fund pharma upside. The real risk is Stelara LOE accelerating, not indefinite medtech drag. If management can push cost-out and automate, margins stabilize by 2026; the key question is pharma durability, not just medtech. That implies the core thesis hinges more on pharma durability than on medtech momentum alone.
J&J's Q2 beat was driven by pharma, particularly Tremfya, but medtech underperformance and Abiomed's decline are concerns. The panel is neutral on the stock, with varying confidence levels.
Pharma momentum, especially Tremfya's growth
Medtech underperformance and Abiomed's decline